Phage Therapy: An Alternative Approach to Combating Multidrug-Resistant Bacterial Infections in Cystic Fibrosis.

Autor: Cocorullo M; Department of Biology and Biotechnology 'Lazzaro Spallanzani', University of Pavia, Via A. Ferrata 9, 27100 Pavia, Italy., Stelitano G; Department of Biology and Biotechnology 'Lazzaro Spallanzani', University of Pavia, Via A. Ferrata 9, 27100 Pavia, Italy., Chiarelli LR; Department of Biology and Biotechnology 'Lazzaro Spallanzani', University of Pavia, Via A. Ferrata 9, 27100 Pavia, Italy.
Jazyk: angličtina
Zdroj: International journal of molecular sciences [Int J Mol Sci] 2024 Jul 30; Vol. 25 (15). Date of Electronic Publication: 2024 Jul 30.
DOI: 10.3390/ijms25158321
Abstrakt: Patients with cystic fibrosis (CF) are prone to developing life-threatening lung infections with a variety of pathogens that are difficult to eradicate, such as Burkholderia cepacia complex (Bcc) , Hemophilus influenzae , Mycobacterium abscessus ( Mab ), Pseudomonas aeruginosa , and Staphylococcus aureus . These infections still remain an important issue, despite the therapy for CF having considerably improved in recent years. Moreover, prolonged exposure to antibiotics in combination favors the development and spread of multi-resistant bacteria; thus, the development of alternative strategies is crucial to counter antimicrobial resistance. In this context, phage therapy, i.e., the use of phages, viruses that specifically infect bacteria, has become a promising strategy. In this review, we aim to address the current status of phage therapy in the management of multidrug-resistant infections, from compassionate use cases to ongoing clinical trials, as well as the challenges this approach presents in the particular context of CF patients.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje